IV CR845: Phase II started

Cara began a 2-part, double-blind, U.S. Phase II trial of IV CR845 in 84 hemodialysis patients with uremic pruritus. The first part will evaluate repeat doses of CR845 over a 1-week period, while the second part will compare CR845 vs. placebo for 2 weeks. Cara plans to start Phase III testing of IV CR845 in acute pain early next year.

The company is developing oral formulations of CR845 for acute and chronic pain. The company has completed a Phase I trial of a capsule formulation of CR845 and began a Phase I trial of a tablet formulation in June. ...